Q3 FY2026 Earnings
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Bright Minds Biosciences(DRUG) the EBIT is -3.655 M (+16.22%), Beat estimate;the EPS is -0.169 (+68.71%), Beat estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
Revenue
TBA--
0.00B--
----
EBITExceed expectations
-0.00B16.22%
-0.01B237.06%
+0.01B253.28%
EPSExceed expectations
-0.16968.71%
-1.2371129.05%
+1.0681197.76%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf